# US 2020/0399389 A1 · Anti-cd73 antibodies and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0399389 A1
- Document ID: US20200399389A1
- Status: Published application
- Kind: A1
- Application number: 15/733,540
- Filed: 2019-03-05
- Published: 2020-12-24
- Earliest claimed: 2018-03-09
- Assignees: Phanes Therapeutics, Inc.
- Applicants: Phanes Therapeutics, Inc.
- Inventors: Minghan WANG; Hui ZOU; Fen PEI
- Web page: https://patentgrep.com/patent/US20200399389A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/74: Inducing cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Anti-CD73 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer.

## Claims

### Claim 1

An isolated monoclonal antibody or antigen-binding fragment thereof comprising a heavy chain complementarity determining region 1 (HCDR1), HCDR2, HCDR3, a light chain complementarity determining region 1 (LCDR1), LCDR2, and LCDR3, having the polypeptide sequences of:
a. SEQ ID NOs:89, 90, 91, 149, 150 and 151, respectively, or SEQ ID NOs:209, 210, 211, 269, 270 and 271, respectively;
b. SEQ ID NOs:41, 42, 43, 101, 102 and 103, respectively, or SEQ ID NOs:161, 162, 163, 221, 222 and 223, respectively;
c. SEQ ID NOs:44, 45, 46, 104, 105 and 106, respectively, or SEQ ID NOs:164, 165, 166, 224, 225 and 226, respectively;
d. SEQ ID NOs:47, 48, 49, 107, 108 and 109, respectively, or SEQ ID NOs:167, 168, 169, 227, 228 and 229, respectively;
e. SEQ ID NOs:50, 51, 52, 110, 111 and 112, respectively, or SEQ ID NOs:170, 171, 172, 230, 231 and 232, respectively;
f. SEQ ID NOs:53, 54, 55, 113, 114 and 115, respectively, or SEQ ID NOs:173, 174, 175, 233, 234 and 235, respectively;
g. SEQ ID NOs:56, 57, 58, 116, 117 and 118, respectively, or SEQ ID NOs:176, 177, 178, 236, 237 and 238, respectively;
h. SEQ ID NOs:59, 60, 61, 119, 120 and 121, respectively, or SEQ ID NOs:179, 180, 181, 239, 240 and 241, respectively;
i. SEQ ID NOs:62, 63, 64, 122, 123 and 124, respectively, or SEQ ID NOs:182, 183, 184, 242, 243 and 244, respectively;
j. SEQ ID NOs:65, 66, 67, 125, 126 and 127, respectively, or SEQ ID NOs:185, 186, 187, 245, 246 and 247, respectively;
k. SEQ ID NOs:68, 69, 70, 128, 129 and 130, respectively, or SEQ ID NOs:188, 189, 190, 248, 249 and 250, respectively;
l. SEQ ID NOs:71, 72, 73, 131, 132 and 133, respectively, or SEQ ID NOs:191, 192, 193, 251, 252 and 253, respectively;
m. SEQ ID NOs:74, 75, 76, 134, 135 and 136, respectively, or SEQ ID NOs:194, 195, 196, 254, 255 and 256, respectively;
n. SEQ ID NOs:77, 78, 79, 137, 138 and 139, respectively, or SEQ ID NOs:197, 198, 199, 257, 258 and 259, respectively;
o. SEQ ID NOs:80, 81, 82, 140, 141 and 142, respectively, or SEQ ID NOs:200, 201, 202, 260, 261 and 262, respectively;
p. SEQ ID NOs:83, 84, 85, 143, 144 and 145, respectively, or SEQ ID NOs:203, 204, 205, 263, 264 and 265, respectively;
q. SEQ ID NOs:86, 87, 88, 146, 147 and 148, respectively, or SEQ ID NOs:206, 207, 208, 266, 267 and 268, respectively;
r. SEQ ID NOs:92, 93, 94, 152, 153 and 154, respectively, or SEQ ID NOs:212, 213, 214, 272, 273 and 274, respectively;
s. SEQ ID NOs:95, 96, 97, 155, 156 and 157, respectively, or SEQ ID NOs:215, 216, 217, 275, 276 and 277, respectively; or
t. SEQ ID NOs:98, 99, 100, 158, 159 and 160, respectively, or SEQ ID NOs:218, 219, 220, 278, 279 and 280, respectively;
wherein the antibody or antigen-binding fragment thereof specifically binds to CD73.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1, comprising a heavy chain variable region having a polypeptide sequence at least 95% identical to SEQ ID NO:286, 33, 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 35, 37, 39, 282, 283, 284, 285, 287, 288, 289, 295, 296, 297, or 298, or a light chain variable region having a polypeptide sequence at least 95% identical to SEQ ID NO:293, 34, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36, 38, 40, 290, 291, 292, 294, or 299.

### Claim 4 (depends on 1)

The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1, comprising:
a. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:286, and a light chain variable region having the polypeptide sequence of SEQ ID NO:293;
b. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:33, and a light chain variable region having the polypeptide sequence of SEQ ID NO:34;
c. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:1, and a light chain variable region having the polypeptide sequence of SEQ ID NO:2;
d. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:3, and a light chain variable region having the polypeptide sequence of SEQ ID NO:4;
e. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:5, and a light chain variable region having the polypeptide sequence of SEQ ID NO:6;
f. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:7, and a light chain variable region having the polypeptide sequence of SEQ ID NO:8;
g. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:9, and a light chain variable region having the polypeptide sequence of SEQ ID NO:10;
h. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:11, and a light chain variable region having the polypeptide sequence of SEQ ID NO:12;
i. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:13, and a light chain variable region having the polypeptide sequence of SEQ ID NO:14;
j. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:15, and a light chain variable region having the polypeptide sequence of SEQ ID NO:16;
k. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:17, and a light chain variable region having the polypeptide sequence of SEQ ID NO:18;
l. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:19, and a light chain variable region having the polypeptide sequence of SEQ ID NO:20;
m. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:21, and a light chain variable region having the polypeptide sequence of SEQ ID NO:22;
n. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:23, and a light chain variable region having the polypeptide sequence of SEQ ID NO:24;
o. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:25, and a light chain variable region having the polypeptide sequence of SEQ ID NO:26;
p. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:27, and a light chain variable region having the polypeptide sequence of SEQ ID NO:28;
q. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:29, and a light chain variable region having the polypeptide sequence of SEQ ID NO:30;
r. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:31, and a light chain variable region having the polypeptide sequence of SEQ ID NO:32;
s. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:35, and a light chain variable region having the polypeptide sequence of SEQ ID NO:36;
t. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:37, and a light chain variable region having the polypeptide sequence of SEQ ID NO:38;
u. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:39, and a light chain variable region having the polypeptide sequence of SEQ ID NO:40;
v. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:282, and a light chain variable region having the polypeptide sequence of SEQ ID NO:290;
w. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:282, and a light chain variable region having the polypeptide sequence of SEQ ID NO:291;
x. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:282, and a light chain variable region having the polypeptide sequence of SEQ ID NO:292;
y. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:283, and a light chain variable region having the polypeptide sequence of SEQ ID NO:290;
z. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:283, and a light chain variable region having the polypeptide sequence of SEQ ID NO:291;
aa. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:283, and a light chain variable region having the polypeptide sequence of SEQ ID NO:292;
bb. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:284, and a light chain variable region having the polypeptide sequence of SEQ ID NO:290;
cc. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:284, and a light chain variable region having the polypeptide sequence of SEQ ID NO:291,
dd. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:284, and a light chain variable region having the polypeptide sequence of SEQ ID NO:292,
ee. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:285, and a light chain variable region having the polypeptide sequence of SEQ ID NO:290,
ff. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:285, and a light chain variable region having the polypeptide sequence of SEQ ID NO:291,
gg. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:285, and a light chain variable region having the polypeptide sequence of SEQ ID NO:292,
hh. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:283, and a light chain variable region having the polypeptide sequence of SEQ ID NO:293,
ii. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:284, and a light chain variable region having the polypeptide sequence of SEQ ID NO:293,
jj. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:285, and a light chain variable region having the polypeptide sequence of SEQ ID NO:293,
kk. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:286, and a light chain variable region having the polypeptide sequence of SEQ ID NO:290,
ll. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:286, and a light chain variable region having the polypeptide sequence of SEQ ID NO:291,
mm. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:286, and a light chain variable region having the polypeptide sequence of SEQ ID NO:292;
nn. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:287, and a light chain variable region having the polypeptide sequence of SEQ ID NO:294,
oo. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:288, and a light chain variable region having the polypeptide sequence of SEQ ID NO:294,
pp. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:289, and a light chain variable region having the polypeptide sequence of SEQ ID NO:294,
qq. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:284, and a light chain variable region having the polypeptide sequence of SEQ ID NO:299,
rr. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:295, and a light chain variable region having the polypeptide sequence of SEQ ID NO:299,
ss. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:296, and a light chain variable region having the polypeptide sequence of SEQ ID NO:299,
tt. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:297, and a light chain variable region having the polypeptide sequence of SEQ ID NO:299, or
uu. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:298, and a light chain variable region having the polypeptide sequence of SEQ ID NO:299.

### Claim 5 (depends on 1)

The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1, wherein the monoclonal antibody or antigen-binding fragment thereof inhibits the enzyme activity of soluble and/or cell-surface CD73, prevents the dimerization of CD73, induces the internalization of CD73, and/or is capable of activating T cells.

### Claim at position 6

6-7. (canceled)

### Claim 8 (depends on 1)

The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof is chimeric or human or humanized.

### Claim at position 8

9-11. (canceled)

### Claim 12 (depends on 1)

An isolated nucleic acid encoding the monoclonal antibody or antigen-binding fragment thereof of claim 1.

### Claim 13 (depends on 12)

A vector comprising the isolated nucleic acid of claim 12.

### Claim 14 (depends on 13)

A host cell comprising the vector of claim 13.

### Claim 15 (depends on 1)

A pharmaceutical composition, comprising the isolated monoclonal antibody or antigen-binding fragment thereof of claim 1 and a pharmaceutically acceptable carrier.

### Claim 16 (depends on 15)

A method of inhibiting the nucleotidase activity of CD73, preventing the dimerization of CD73, inducing the internalization of CD73, or treating cancer in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of claim 15.

### Claim at position 14

17-19. (canceled)

### Claim 20 (depends on 1)

A method of producing the monoclonal antibody or antigen-binding fragment thereof of claim 1, comprising culturing a cell comprising a nucleic acid encoding the monoclonal antibody or antigen-binding fragment under conditions to produce the monoclonal antibody or antigen-binding fragment, and recovering the antibody or antigen-binding fragment from the cell or culture.

### Claim 21 (depends on 1)

A method of producing a pharmaceutical composition comprising the monoclonal antibody or antigen-binding fragment of claim 1, comprising combining the monoclonal antibody or antigen-binding fragment with a pharmaceutically acceptable carrier to obtain the pharmaceutical composition.

### Claim 22 (depends on 1)

A method of determining a level of CD73 or determining the ecto-5′ nucleotidase activity of CD73 in a subject, the method comprising:
a. obtaining a sample from the subject;
b. contacting the sample with an isolated monoclonal antibody or antigen-binding fragment thereof of claim 1; and
c. determining a level of CD73 or determining the ecto-5′ nucleotidase activity of CD73 in the subject.

### Claim 23 (depends on 22)

The method of claim 22, wherein the sample is a tissue sample or a blood sample.

### Claim 24 (depends on 23)

The method of claim 23, wherein the tissue sample is a cancer tissue sample.

### Claim at position 20

25-29. (canceled)

### Claim 30 (depends on 1)

An isolated bispecific antibody or antigen-binding fragment thereof comprising the monoclonal antibody or antigen-binding fragment thereof of claim 1.

### Claim 31 (depends on 31)

An isolated nucleic acid encoding the bispecific antibody or antigen-binding fragment thereof of claim 31.

### Claim 32 (depends on 32)

A vector comprising the isolated nucleic acid of claim 32.

### Claim 33 (depends on 33)

A host cell comprising the vector of claim 33.

### Claim 34 (depends on 31)

A pharmaceutical composition comprising the isolated bispecific antibody or antigen-binding fragment thereof of claim 31 and a pharmaceutically acceptable carrier.